NCT06471127Recruiting
Neuroplasticity Biomarkers in Aphasia
Genetic and MRI Biomarkers of Neuroplasticity Predict Aphasia Recovery and Phenotypes
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity. The proposed work will evaluate genetic and neural network biological markers of neuroplasticity associated with variability in aphasia, with a future goal to improve prognostics and identify therapeutic targets to reduce the long-term burdens of aphasia.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 17 Jun 2024
- Start date
- 17 Mar 2025
- Primary completion date
- 31 May 2029
- Lead sponsor
- University of Wisconsin, Madison
- Diseases
- Stroke
- NCT number
- NCT06471127
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 17 Mar 2025 to the primary completion date, 31 May 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current abuse of alcohol or drugs, prescription or otherwise
Other illness
- History of significant medical or neurological disorder (other than stroke)
- History of significant or poorly controlled psychiatric disorders
- Anything other than standard of care stroke treatment such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications or choles- terol-lowering agents, thrombolytics (e.g., tPA), anticoagulation agents such as Heparin, Warfarin/Coumadin
Other
- Clinically significant and uncorrected vision or hearing loss
Who the study is looking for
- Ages 40-90
- Right-handed (prior to stroke)
- Proficient English speakers
- History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere.
- Presence of aphasia (Aims 2-3)
- Capacity to understand the nature of the study and provide informed consent
- Acute or subacute stroke at the time of Aim 1 enrollment; Stroke #12 months old (chronic) at the time of Aims 2-3 enrollment
- Medically stable
Age in the registry: 40 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UW School of Medicine and Public Health Coordinator of this site? Confirm its status | Madison | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.